Osteoarthritic (OA) pain represents the second-largest segment of the overall chronic pain market, affecting more than 70 million patients with OA in the G7. The OA pain market represents a lucrative opportunity for drug developers given the residual unmet need for more-effective and safe therapies, particularly agents that offer a distinct mechanism of action that more strongly correlates with the nature of this type of pain. OA pain is predominately treated with cost-effective generic nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics, although branded agents such as costly abuse-deterrent reformulations of opioid analgesics and new combinations of existing NSAIDs that attempt to mitigate side effects are also frequently prescribed. Emerging therapies, such as biological drugs from Regeneron/Teva/Mitsubishi Tanabe Pharma and Pfizer/Eli Lilly that target nerve growth factor (NGF), together with the increasing number of patients diagnosed with OA pain due to lifestyle influences, will be key drivers of market growth through 2026.
Questions Answered:
How do interviewed experts perceive the OA pain marketplace to be changing given the emphasis on the risk of abuse/misuse with opioid analgesics?
What effect will the recent launches of new analgesics such as Iroko’s Vivlodex and Purdue’s Hysingla ER continue to have on the treatment paradigm?
What will be the impact of a new drug class, the emerging anti-NGF biologic therapies, on the treatment landscape, given their reputed robust efficacy but considering also lingering concerns over safety seen in initial testing?
What market share can developers of emerging therapies expect to obtain in the large patient population? What are the key drivers and constraints in the OA pain market?
Product Description:
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.